Pfizer ( Pfizer )


Pfizer's picture

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

Pfizer press release, blog etc

04/12/2018 - 06:00 Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
04/10/2018 - 11:33 Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
04/10/2018 - 07:13 Pfizer Signs Lease for the Spiral at Hudson Yards in Manhattan
04/04/2018 - 06:48 U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
04/03/2018 - 07:48 Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizers Allogeneic CAR T Immuno-oncology Portfolio
03/29/2018 - 07:43 Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
03/23/2018 - 04:54 Pfizer Reports Top-Line Results from a Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers
03/20/2018 - 07:26 Pfizer Invites Public To View And Listen To Webcast Of May 1 Conference Call With Analysts
03/19/2018 - 14:15 U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
03/05/2018 - 15:01 Dan R. Littman Elected to Pfizers Board of Directors
02/23/2018 - 10:49 Pfizer Announces Update on European Marketing Authorization Application for SUTENT (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
02/23/2018 - 10:40 Albert Bourla Elected to Pfizers Board of Directors
02/23/2018 - 10:04 Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG and BOSULIF
02/14/2018 - 06:21 Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
02/12/2018 - 08:23 U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizers Third-Generation ALK Inhibitor Lorlatinib
02/05/2018 - 15:46 Phase 3 PROSPER Trial Shows XTANDI (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
01/08/2018 - 12:49 Pfizer Establishes New Partnering Model for Early-Stage Academic Research
01/08/2018 - 12:20 Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents